BIO Asia-Taiwan
BIO Asia-Taiwan | July 15-19, 2026 | Taipei (TWN)
Mabion is pleased to announce our participation in BIO Asia–Taiwan 2026, taking place 15–19 July 2026 in Taipei, Taiwan. We would be honored to meet with you during the event to explore opportunities for collaboration and discuss how our organizations may work together.
Mabion is a European biotechnology company specializing in the development and manufacturing of large molecules, with particular expertise in antibody-based medicines. We recognize the strategic importance of the Asian life sciences market and have been actively strengthening our presence in the region.
In March 2026, Mabion secured a three-year financing agreement of up to EUR 3.1 million from CBC Co., Ltd. of Tokyo, reflecting the confidence of an established Asian partner in our long-term development. In addition, our collaboration with KriSan Biotech in the field of Antibody-Drug Conjugates (ADCs) further demonstrates our commitment to advancing innovative technologies together with partners in Asia.
These strong connections make the Asian market particularly important to Mabion and reinforce our interest in building lasting partnerships in both innovative biologics and biosimilars development.
Mabion representatives at the event will be:
- Gregor Kawaletz, Chief Executive Officer
- Anna Czubatka-Bieńkowska, Director of Project Management Department
- Paulina Toboła, Analytics Development Division Manager
The participation of Mabion’s CEO underlines the company’s serious approach to development opportunities in Asia and its readiness to engage in concrete discussions with potential partners. Our team will be available to discuss new projects, strategic collaborations, technology partnerships, and drug substance manufacturing opportunities. We are prepared to engage in discussions and move promising opportunities forward without delay.
We sincerely look forward to the opportunity to meet you in Taipei.
Check out the BIO Asia website for more details.